1 / 26

Global Infectious Disease

Global Infectious Disease. Dr. Cynthia Schneider Life Science Seminar October 21, 2004. The Facts. The Facts. The Facts. Infectious Disease and the Developing World . 90/10. 90% of global health care focus on 10% of the population 90% of global population receives 10% of health care.

Mia_John
Download Presentation

Global Infectious Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Infectious Disease Dr. Cynthia Schneider Life Science Seminar October 21, 2004

  2. The Facts

  3. The Facts

  4. The Facts

  5. Infectious Disease and the Developing World

  6. 90/10 • 90% of global health care focus on 10% of the population • 90% of global population receives 10% of health care

  7. Malaria: a Case Study in Infectious Disease

  8. Malaria: the “Silent Holocaust”

  9. And It’s Getting Worse • Average number of cases per year has quadrupled since 1980s • Malaria deaths among children in eastern and southern Africa has doubled • In some areas rate of increase of malaria deaths as high as 11-fold • 95-100% of population of tropical Africa at risk of malaria • At present rate of increase, half of the world’s population soon will live in malaria infected areas

  10. Poverty and Malaria

  11. Malaria-endemic Countries in Africa, the Middle East, Asia, and the South Pacific, 2002 www.cdc.gov

  12. Malaria-endemic Countries in the Americas, 2002

  13. History of Battling Malaria • Malaria eliminated in US by draining swamps • Early 20th century, organized malaria control • Global eradication campaign 1956-1973 failed • Chloroquine - cheap, effective treatment (5 cents per dose) until evolution of chloroquine resistant mosquitoes • From 1990 onwards, increasing problem in Africa • Multi-pronged approach: vector, prevention (vaccine, spraying, nets) , drugs for treatment

  14. Battling Malaria Today : the Players • Gates Foundation, Malaria Vaccine Initiative: • Assumptions (source: Gates Foundation web site) • A strong foundation of malaria research already exists; • Progress along the malaria vaccine development pathway will be measurable; • Current market forces requiring a return on investment cannot drive malaria vaccine development alone, requiring a balance of push and pull mechanisms for success; and • Effective disease prevention will ultimately require combination vaccines that include several antigens from different stages of the Plasmodium life cycle and elicit a breadth of immune responses.

  15. Gates Foundation MVI • Approach • Partnerships • Vaccine Development, not Discovery • Pursues multiple vaccine candidates simultaneously • Uses industrial model of management with goal of ensuring that MVI funding results in net increase in funding for vaccine development

  16. Gates Partners • PATH – international NGO for sustainable, culturally sensitive solutions to health problems in developing world • Glaxo Smith Kline (GSK) • GAVI Global Alliance for Vaccines and Immunization • Mozambique – GSK Biologicals, Mozambique Ministry of Health, Centro de Investigacao em Saude da Manhica (CISM), Hospital Clinic of the University of Barcelona

  17. Gates Funding for Malaria • MVI at PATH 50 million over 4 years (4/1/99) • 100 million over 4 years (9/21/2003) • Other grants, such as to One World Health –1.4 million • Compared to total funding for malaria – about 80 million in 2004

  18. The Players MMV –Medicines for Malaria • Swiss Foundation established 1999 • Public Private Partnership • WHO, IFPMA (International Federation of Pharmaceutical Manufacturers Association), Global Forum for Health Research, Rockefeller Foundation, World Bank, Swiss Agency for Development and Cooperation, Association of the British Pharmaceutical Industry, Wellcome Trust • Formed as alternative to market mechanisms, which have not led to vaccine development

  19. RBM –Roll Back Malaria • 1998- WHO, UNICEF, UNDP, World Bank, plus 90 other partners • Goal to halve malaria by 2010 • Multi-faceted Strategy, with emphasis on “low tech’ interventions: • Preventive treatment during pregnancy • Artemisinin-based combination therapy for treatment • Vector control • Insect-treated nets • Indoor residual spraying

  20. “Low Tech” Weapons Against Malaria • Artemisinin • Mosquito nets • DDT

  21. Artemisinin – an organic antidote to chloroquine resistance • Artemisinin and artesunate come from an herb used in traditional Chinese medicine • Combat chloroquine resistance • Works best when combined with another anti-malarial • Artemisinin in combination with other anti-malarials has cure rate of 90% • PROBLEM: Artemisinin currently grown in Tanzania, exported to Europe for processing, re-imported to Africa at prohibitive cost of $5-7 per dose

  22. Policy Choices: Whose Standards Are They Anyway? • DDT -- arguably readiest, cheapest means to combat malaria • Not used in developing world because of regulatory standards in developed world • Northern/western driven environmental standards have (inadvertent) impact on health in developing world • How to balance environmental safety and human health? • Risk evaluation that incorporates risk of doing nothing

  23. Another approach -- modify the vector • Genetically alter mosquito so that it cannot transmit disease (prevents malaria parasite from binding onto mosquito’s gut; interrupts malaria life cycle) • Genetically alter mosquito so that it produces more defensin, which kills malaria bacteria (like a vaccine imbedded in mosquito) • Problems: How to regulate? How to ensure environmental safety?

  24. Role of Department of Defense • “New” vaccine recently tested in Mozambique was developed at Walter Reed • DOD operates largest malaria drug development program in world, emphasis on drug resistance (IOM Emerging Infectious Diseases from the Global to the Local Perspective, 1999) • DOD has large network of state-of-art labs all over world -- 700 staff, with 800 in DOD who work with them on infectious diseases • Focus on safety of troops has led to comprehensive surveillance/monitoring system • Links to WHO and other health agencies

  25. Flu Vaccine Crisis Reveals U.S. Vulnerability Systemic problems with vaccines: 1) high cost of manufacturing and passing regulatory hurdles; 2) limited U.S. and foreign markets; 3) Product liability exposure.

  26. Towards a Different Model • Need to create incentives for more private companies to develop vaccines • Requires creative rethinking of public/private balance and roles • How to create incentives for more public and private entities to tackle infectious diseases in developing world • How to balance western/northern regulation standards with needs and capacities of developing world

More Related